SS Innovations International, Inc. Achieves Another Milestone by Successfully Performing Over 2,000 km North-to-South Robotic Cardiac Telesurgery with its SSi Mantra 3 Surgical Robotic System
SS Innovations International (OTC: SSII) has achieved a significant milestone by successfully performing India's first North-to-South robotic cardiac telesurgery using its SSi Mantra 3 Surgical Robotic System. The procedure connected the company's headquarters in Gurugram to Aster CMI Hospital in Bengaluru, spanning over 2,000 kilometers.
The 2-hour-40-minute surgery involved closing a complex Atrial Septal Defect in a 35-year-old patient. Led by Dr. Sudhir Srivastava from Gurugram and supported by Dr. Arul Furtado's team in Bengaluru, the procedure demonstrated exceptional precision with minimal latency.
The SSi Mantra 3, India's first CDSCO-approved surgical robotic system for telesurgery, represents a significant advancement in making specialized surgical care accessible across long distances. This achievement follows previous successful telesurgeries spanning 40 km and 286 km, marking a substantial leap in remote surgical capabilities.
SS Innovations International (OTC: SSII) ha raggiunto un traguardo significativo eseguendo con successo la prima telesurgery cardiaca robotica da Nord a Sud in India utilizzando il suo SSi Mantra 3 Surgical Robotic System. La procedura ha collegato la sede dell'azienda a Gurugram con l'Aster CMI Hospital di Bengaluru, coprendo oltre 2.000 chilometri.
La chirurgia, durata 2 ore e 40 minuti, ha coinvolto la chiusura di un complesso difetto del setto atriale in un paziente di 35 anni. Guidata dal Dr. Sudhir Srivastava di Gurugram e supportata dal team del Dr. Arul Furtado a Bengaluru, la procedura ha dimostrato un'eccezionale precisione con una latenza minima.
Il SSi Mantra 3, il primo sistema robotico chirurgico approvato dal CDSCO in India per la telesurgery, rappresenta un significativo progresso nell'accesso a cure chirurgiche specializzate su lunghe distanze. Questo risultato segue precedenti telesurgery di successo che coprivano 40 km e 286 km, segnando un notevole salto nelle capacità chirurgiche a distanza.
SS Innovations International (OTC: SSII) ha alcanzado un hito significativo al realizar con éxito la primera telesurgery cardíaca robótica de Norte a Sur en India utilizando su SSi Mantra 3 Surgical Robotic System. El procedimiento conectó la sede de la empresa en Gurugram con el Aster CMI Hospital en Bengaluru, abarcando más de 2,000 kilómetros.
La cirugía, que duró 2 horas y 40 minutos, consistió en cerrar un complejo defecto del septo auricular en un paciente de 35 años. Liderada por el Dr. Sudhir Srivastava de Gurugram y apoyada por el equipo del Dr. Arul Furtado en Bengaluru, el procedimiento demostró una precisión excepcional con una latencia mínima.
El SSi Mantra 3, el primer sistema robótico quirúrgico aprobado por el CDSCO en India para telesurgery, representa un avance significativo en el acceso a atención quirúrgica especializada a largas distancias. Este logro sigue a telesurgeries previas exitosas que abarcaron 40 km y 286 km, marcando un salto sustancial en las capacidades quirúrgicas remotas.
SS Innovations International (OTC: SSII)는 인도의 첫 번째 북남 로봇 심장 원격 수술을 성공적으로 수행하며 중요한 이정표를 세웠습니다. 이 수술은 SSi Mantra 3 Surgical Robotic System을 사용하여 회사 본사가 있는 구르가온과 벵갈루루의 아스터 CMI 병원을 연결하며 2,000킬로미터 이상을 아우릅니다.
2시간 40분 동안 진행된 이 수술은 35세 환자의 복잡한 심방 중격 결손을 닫는 작업이었습니다. 구르가온의 수디르 스리바스타바 박사가 이끌고 벵갈루루의 아룰 푸르타도 박사 팀이 지원하여 진행된 이 절차는 최소한의 지연으로 뛰어난 정밀성을 보여주었습니다.
SSi Mantra 3는 원격 수술을 위한 인도 최초의 CDSCO 승인 로봇 수술 시스템으로, 장거리에서 전문적인 수술 치료를 접근 가능하게 만드는 데 중요한 발전을 나타냅니다. 이 성과는 40km 및 286km에 걸친 이전의 성공적인 원격 수술에 이어지는 것으로, 원거리 수술 능력의 상당한 도약을 의미합니다.
SS Innovations International (OTC: SSII) a atteint un jalon significatif en réalisant avec succès la première télésurgery cardiaque robotique d'Inde, reliant le nord au sud, grâce à son SSi Mantra 3 Surgical Robotic System. La procédure a relié le siège de l'entreprise à Gurugram à l'hôpital Aster CMI à Bengaluru, sur une distance de plus de 2 000 kilomètres.
La chirurgie, qui a duré 2 heures et 40 minutes, a consisté à fermer un complexe défaut du septum auriculaire chez un patient de 35 ans. Dirigée par le Dr Sudhir Srivastava de Gurugram et soutenue par l'équipe du Dr Arul Furtado à Bengaluru, la procédure a démontré une précision exceptionnelle avec une latence minimale.
Le SSi Mantra 3, le premier système robotique chirurgical approuvé par le CDSCO en Inde pour la télésurgery, représente un progrès significatif pour rendre les soins chirurgicaux spécialisés accessibles sur de longues distances. Ce succès fait suite à des télésurgeries précédentes réussies couvrant 40 km et 286 km, marquant un saut considérable dans les capacités chirurgicales à distance.
SS Innovations International (OTC: SSII) hat einen bedeutenden Meilenstein erreicht, indem es Indiens erste nord-südliche robotergestützte Herz-Telegesundheitsoperation erfolgreich durchgeführt hat, unter Verwendung des SSi Mantra 3 Surgical Robotic System. Der Eingriff verband den Hauptsitz des Unternehmens in Gurugram mit dem Aster CMI Hospital in Bengaluru und erstreckte sich über mehr als 2.000 Kilometer.
Die 2 Stunden und 40 Minuten dauernde Operation beinhaltete das Schließen eines komplexen Vorhofseptumdefekts bei einem 35-jährigen Patienten. Unter der Leitung von Dr. Sudhir Srivastava aus Gurugram und unterstützt von Dr. Arul Furtados Team in Bengaluru zeigte das Verfahren außergewöhnliche Präzision mit minimaler Latenz.
Das SSi Mantra 3, Indiens erstes vom CDSCO genehmigtes chirurgisches Robotersystem für Telegesundheitsoperationen, stellt einen bedeutenden Fortschritt dar, um spezialisierte chirurgische Versorgung über große Entfernungen zugänglich zu machen. Dieser Erfolg folgt auf frühere erfolgreiche Telegesundheitsoperationen über 40 km und 286 km und markiert einen erheblichen Sprung in den Möglichkeiten der Fernchirurgie.
- Successfully performed first North-to-South robotic cardiac telesurgery over 2,000 km distance
- Received CDSCO approval for telesurgery operations in India
- System demonstrates minimal latency over long distances
- FDA and CE Mark approval anticipated in second half of 2025
- System validated in more than 90 different types of surgical procedures
- FDA and CE Mark approvals still pending for international markets
- The SSI Mantra 3 Surgical Robotic System enabled a seamless connection from SS Innovations headquarters in Gurugram, India to Aster CMI Hospital in Bengaluru, India covering a distance over 2,000 km.
- The SSi Mantra, India’s first CDSCO*-approved surgical robotic system for telesurgery, brings precision and accessibility to complex surgical procedures.
FORT LAUDERDALE, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative robotic surgical technologies dedicated to making world-class robotic surgery affordable for and accessible to a global population, announced that it successfully performed India’s first North-to-South robotic cardiac telesurgery. Made possible by our advanced SSi Mantra 3 Surgical Robotic System, this landmark procedure bridged a 2,000-kilometer distance between SS Innovations headquarters in Gurugram, New Delhi and the Aster CMI Hospital in Bengaluru with imperceptible latency. This achievement is a milestone in making cutting-edge robotic surgical-care accessible across long distances. The Company believes that the successful performance of this critical robotic cardiac telesurgery opens the door to significant advancements in Indian healthcare, paving the way for a future where advanced surgical technology plays a vital role in making healthcare more accessible and efficient worldwide.
The long distance robotic assisted intracardiac telesurgery, was performed on a 35-year-old patient, lasted for 2 hours and 40 minutes and involved closing a complex Atrial Septal Defect (ASD) which is a congenital condition where there is a small hole between the two upper chambers of the heart. The procedure was led by Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations from Gurugram, supported by Dr. Arul Furtado, Consultant - Cardiovascular & Thoracic Surgery at Aster CMI Hospital, Bengaluru, along with his expert team. The surgery demonstrated exceptional precision, achieving an incredibly low latency, further underscoring the accuracy and efficiency of robotic-assisted remote surgery.
Expressing immense gratitude for making life-saving procedures accessible beyond boundaries, SS Innovations Founder, Chairman, and CEO, Dr. Sudhir Srivastava, said, “This is a defining moment for the future of surgical care in India. With telesurgery powered by the SSi Mantra 3—designed for India, for the world, we are bridging healthcare gaps and ensuring world-class surgical expertise reaches even the most remote areas. By seamlessly connecting North to South India, we have demonstrated how distance is no longer a barrier to advanced medical care. With approval from the CDSCO (the Central Drugs Standard Control Organization, India’s equivalent of the U.S. FDA), we are not just pushing technological boundaries but fulfilling our mission to democratize robotic surgery. Telesurgery is revolutionizing healthcare, eliminating the need for patients to travel and making advanced surgical care truly accessible and affordable.”
Dr. Arul Furtado, Consultant Cardiac Surgeon, Aster CMI Hospital, Bengaluru, added, "Performing our first robotic intracardiac telesurgery for an Atrial Septal Defect on a young patient in his mid-thirties was both a valuable learning experience and a significant milestone for our institution. As our first approach into robotic cardiac telesurgery, the experience was seamless, and the SSi Mantra 3 Surgical Robotic System proved to be incredibly user-friendly, allowing us to perform the procedure with precision and confidence. The team was highly encouraged by the success of this telesurgery, reinforcing the vital role we believe robotic-assisted surgery will play in the future of cardiac care. What sets the SSi Mantra 3 apart from other robotic platforms is its design—developed by a cardiac surgeon with extensive experience in robotic cardiac surgery. This unique insight gives it a distinct advantage, making it highly adaptable and tailored to the needs of cardiac surgeons. As we move forward, I believe robotic telesurgery has the ability to redefine access to specialized surgical care, and today’s procedure marks just the beginning of this transformation."
SS Innovations' journey in telesurgery began with an initial procedure at Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) in Delhi, remotely executed from the SSI office in Gurugram, covering a distance of 40 km. Building on this success, the next milestone connected SS Innovations headquarters in Gurugram with Manipal Hospital in Jaipur, Rajasthan, spanning 286 km. Now, India has witnessed achieving another historic feat – a robotic-assisted telesurgery conducted over 2,000+ km from the Company’s headquarters in Gurugram in North India to Bengaluru at Aster CMI Hospital in South India, performed with no observable latency and real-time precision using the SSi Mantra 3 Surgical Robotic System demonstrating the future potential of remote surgical care. By enabling real-time expertise shared through telesurgery and tele-proctoring, SS Innovations is addressing gaps in surgical access and precision. The successful tele-surgeries performed to date highlight the potential of advanced robotic technologies to enhance precision and quality in surgical interventions. Telesurgery not only overcomes geographical constraints but also reduces the need for patients to travel long distances for specialized medical care.
This historic achievement marks a significant step forward in India’s healthcare landscape, with SS Innovations leading the charge in revolutionizing surgical care through the use of advanced robotic technology coupled with a humanitarian vision. With the capability of performing telesurgeries across distances of thousands of kilometers, new possibilities are opened for accessible, high-quality healthcare across India and globally. As SS Innovations continues to enhance its technologies, the focus remains on practical solutions that enhance surgical efficiency, expand access to specialized care, and improve patient outcomes across India and beyond.
About SS Innovations International, Inc.:
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative robotic surgical technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SS Innovations’ business operations are headquartered in India and the Company plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit our website at ssinnovations.com or LinkedIn for updates.
About the SSi Mantra:
The SSi Mantra Surgical Robotic System, by SS Innovations, is a modular multi-arm system with many advanced technology features. It allows for the use of 3-5 robotic arms, has an open-faced ergonomic Surgeon Command Centre, 32-inch large 3D 4K monitor, a 23-inch 2D Touch panel monitor for all patient related information display, a virtual real-time image of the robotic Patient Side Arm Carts, and the ability for superimposition of 3D models of diagnostic imaging. The Vision Cart gives the table-side team the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The modular robotic arms give flexibility in positioning and the number of arms to be used. This allows for collision-free conduct of surgical operations. There are over 40 different types of robotic endo-surgical instruments that can be used for different specialties including cardiac surgery. The learning curve for surgeons is shorter due to the SSi Mantra’s ergonomic design and user-friendly features.
The SSi Mantra has been clinically validated in India in more than 90 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving FDA approval to market and CE Mark approval in the second half of 2025.
Follow us on:
LinkedIn: https://www.linkedin.com/company/ssinnovationsgroup/
YouTube: https://www.youtube.com/@ssinnovations
For media inquiries, please contact:
+1-212-739-0300
FAQ
What milestone did SS Innovations (SSII) achieve with its robotic surgery system?
How long did SSII's robotic cardiac telesurgery procedure take?
What regulatory approvals does SSII's SSi Mantra 3 system currently have?
How many surgical procedures has SSII's robotic system been validated for?
What previous telesurgery distances has SSII's system achieved before the 2,000 km milestone?
